Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
1999-11-04
2001-10-16
Werman, Edward J. (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S403000
Reexamination Certificate
active
06303624
ABSTRACT:
TECHNICAL FIELD
The present invention relates to a pharmaceutical composition for the prevention and/or treatment of hyperphosphatemia which comprises an adenosine antagonist compound or a salt thereof as an active ingredient and so is useful in the pharmaceutical field.
BACKGROUND ART
In the treatment of hyperphosphatemia, calcium preparations are in broad use today.
Calcium preparations have the drawback that they induce hypercalcemia to promote ectopic calcification, which imposes limits on their dosage. As an additional disadvantage, those preparations inhibit absorption of iron to encourage progression of renal anemia.
In the medical scene, a drug which is free from these defect and effective for the treatment of hyperphosphatemia is demanded, and this invention has for its object to fulfill this need.
DISCLOSURE OF INVENTION
The inventors of the present invention discovered for the first time that antagonists of adenosine receptors are effective in preventing and/or treating hyperphosphatemia and secondary hyperparathyroidism, inclusive of their accessory disorders and symptoms, and have accordingly developed this instant invention. The present invention, therefore, accomplishes the above object by providing a pharmaceutical composition comprising an adenosine antagonist compound or a salt thereof as its active ingredient.
The present invention is carried into practice by administering an adenosine antagonist compound or a salt thereof, or a pharmaceutical composition containing an adenosine antagonist or a salt thereof as an active ingredient, to a human being or an animal.
The term “adenosine antagonist” is used herein to mean a substance which opposes adenosine in the binding to the receptors of adenosine, and many substances of this kind are known and generally subsumed in the concept of “adenosine antagonist” by any one skilled in the art.
In the present invention, such an adenosine antagonist is used as the active ingredient but the preferred is an adenosine A
1
receptor antagonist. The term “adenosine A
1
antagonist” as used herein means an adenosine antagonist having a preferentially high affinity for adenosine A
1
receptors.
The preferred example for use in the practice of the present invention, among such adenosine A
1
receptor antagonists, is the pyrazolopyridine compound of the following general formula (I), or its salt.
[wherein
R
1
is lower alkyl, aryl which may have one or more suitable substituents or a heterocyclic group,
R
2
is a group of the formula:
(wherein
R
4
is protected amino or hydroxy, and
R
5
is hydrogen or lower alkyl); cyano;
a group of the formula:
—A—R
6
(wherein R
6
is acyl, and
A is lower aliphatic hydrocarbon group which may have one or more suitable substituents);
amidated carboxy group;
unsaturated heterocyclic group which may have one or more suitable substituents;
amino; or protected amino, and
R
3
is hydrogen, lower alkyl, lower alkoxy or halogen].
As specific examples of said pyrazolopyridine compound (I), those known compounds which are described in Japanese laid-open (Kokai Tokkyo Koho) No. S64-45385, H2-243689, H4-253978 and H5-112566, and WO 95/18128 can be mentioned.
Suitable salts of pyrazolopyridine compound (I) for the purposes of this invention are the conventional kinds of pharmaceutically acceptable salts, and include salts with metals such as alkali metals (e.g. sodium, potassium, etc.) or alkaline earth metals (e.g. calcium, magnesium, etc.), ammonium salts, salts with organic bases (e.g. trimethylamine, triethylamine, pyridine, picoline, dicyclohexylamine, N,N′-dibenzylethylenediamine, etc.), salts with organic acids (e.g. acetic acid, trifluoroacetic acid, maleic acid, tartaric acid, fumaric acid, methanesulfonic acid, benzenesulfonic acid, formic acid, toluenesulfonic acid, etc.), salts with inorganic acids (e.g. hydrochloric acid, hydrobromic acid, hydriodic acid, sulfuric acid, phosphoric acid, etc.), and salts with amino acids (e.g. arginine, aspartic acid, glutamic acid, etc.), etc.
In the above and following descriptions of the present specification, the various definitions falling within the scope of this invention and the preferred examples thereof as well as relevant comments are given below.
The term “lower” means 1 through 6 carbon atoms unless otherwise specified.
The term “higher” means 7 through 20 carbon atoms unless otherwise specified.
Suitable “lower aliphatic hydrocarbon group” may include the lower alkyl, lower alkenyl and lower alkinyl groups mentioned below.
Suitable “lower alkyl group” may include straight-chain or branched-chain alkyl groups such as methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl and hexyl. The preferred example, among them, may be (C
1
-C
4
) alkyl groups and the more preferred one may be methyl, ethyl, propyl and isopropyl.
Suitable “lower alkenyl group” may include straight-chain or branched-chain alkenyl groups such as vinyl, 1-methylvinyl, 2-methylvinyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-methyl-1-propenyl, 1,3-butadienyl, 1-pentenyl, 4-pentenyl, 1-hexenyl, 1,4-hexadienyl and 5-hexenyl. The preferred example, among them, may be (C
2
-C
4
) alkenyl groups and the more preferred one may be vinyl, 1-methylvinyl, 2-methylvinyl and 1,3-butadienyl.
Suitable “lower alkynyl group” may include straight-chain or branched-chain alkynyl groups such as ethynyl, 1-propynyl, 1-methylethynyl, 2-butynyl, 2-methyl-3-butynyl, 2-pentynyl and 1-hexynyl. The preferred example may be (C
2
-C
4
) alkynyl groups and the more preferred one may be ethynyl.
The “lower aliphatic hydrocarbon group” mentioned above may have one or more, preferably 1 through 3, suitable substituents such as halogen atoms (e.g. chloro, bromo, fluoro and iodo).
Suitable “protected amino group” may include lower alkylamino groups such as methylamino, ethylamino, propylamino, butylamino, tert-butylamino, pentylamino, hexylamino, etc.; di(lower)alkylamino groups such as dimethylamino, diethylamino, N-ethylpropylamino, dibutylamino, N-(tert-butyl)pentylamino, dihexylamino, etc.; and those protected amino groups as protected with the conventional amino-protecting groups, such as the acylamino groups mentioned below.
Suitable “acylamino group” may include ureido; lower alkanoylamino groups such as formylamino, acetylamino, propionylamino, butyrylamino, isobutyrylamino, pivaloylamino, hexanoylamino, etc.; lower alkoxycarbonylamino groups such as methoxycarbonylamino, ethoxycarbonylamino, propoxycarbonylamino, tert-butoxycarbonylamino, pentyloxycarbonylamino, hexyloxycarbonylamino, etc.; lower alkoxycarbonyl(lower)alkanoylamino groups such as methoxycarbonylacetylamino, ethoxycarbonylacetylamino, 2-(propoxycarbonyl)propionylamino, 4-(tert-butoxycarbonyl)butyrylamino, 2-(butoxycarbonylmethyl)propionylamino, 2-methyl-2-(pentyloxycarbonylmethyl)propionylamino, 6-hexyloxycarbonylhexanoylamino, etc.; and lower alkanesulfonylamino groups such as methanesulfonylamino, ethanesulfonylamino, propanesulfonylamino, butanesulfonylamino, tert-butanesulfonylamino, pentanesulfonylamino, hexanesulfonylamino, etc., among others.
The “lower alkanoylamino group” mentioned above may have suitable substituents such as di(lower)alkylamino groups (e.g. dimethylamino, N-methyl-N-ethylamino, dipropylamino, di-tert-butylamino, N-pentyl-N-hexylamino, etc.) and cyclic amino groups which may have lower alkyl (e.g. piperidino etc.)etc. Suitable example of said “lower alkanoylamino group having suitable substituents” may be lower alkanoylamino groups having di(lower)alkylamino, such as dimethylaminocarbonylamino, 2-dimethylaminoacetylamino, 2-(N-methyl-N-ethylamino)acetylamino, 2-dimethylaminopropionylamino, 3-dipropylaminobutyrylamino, 2-(di-tert-butylamino)-2-methylpropionylamino, 2-dimethylaminomethyl-2-methylpropionylamino, 6-(N-pentyl-N-hexylamino)hexanoylamino, etc. and lower alkanoylamino groups having a cyclic amino group optionally having lower alkyl, such as piperidinocarbonylamino, 2-piperidinoacetylamino, 2-(2-methylpiperidino)acetylamino, 2-(2-ethylpiperidino)acetylamino, 2-piperidinopropionylamino,
Kajiho Tokuaki
Nakazi Kazumi
Nomura Kazuhiko
Sasaki Emiko
Fujisawa Pharmaceutical Co. Ltd.
Nguyen Helen
Oblon & Spivak, McClelland, Maier & Neustadt P.C.
Werman Edward J.
LandOfFree
Preventives and remedies for hyperphosphatemia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Preventives and remedies for hyperphosphatemia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Preventives and remedies for hyperphosphatemia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2572598